CARVYKTI® is the First and Only BCMA-Targeted Treatment …
2024年4月6日 · CARVYKTI ® is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient's own T-cells with a transgene encoding chimeric antigen receptor (CAR)...
FDA Approves Carvykti CAR T-Cell Therapy for Multiple Myeloma
2022年3月30日 · Patients with advanced multiple myeloma now have a second option for CAR T-cell therapy, a type of personalized immunotherapy. On February 28, the Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for adults with multiple myeloma that is not responding to treatment or has returned after treatment .
CARVYKTI® is the First and Only Cell Therapy to Significantly …
2024年9月27日 · Landmark CARTITUDE-4 study results show CARVYKTI® reduced the risk of death by 45 percent after three-year follow-up. Late-breaking data featured in an oral presentation at the 21st International...
J&J, Legend's Carvykti quickly leaps ahead of BMS' rival CAR-T
2024年4月8日 · With an approval Friday, Carvykti has become the first BCMA-directed therapy for multiple myeloma patients who have received at least just one prior line of therapy. To be eligible, a patient’s...
U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), …
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy ...
Health Canada Authorizes CARVYKTI® (ciltacabtagene …
2 天之前 · Johnson & Johnson Logo (CNW Group/Janssen Inc.) CARVYKTI ® previously received a Notice of Compliance with conditions (NOC/c) from Health Canada for the treatment of adult patients with multiple ...
FDA approves ciltacabtagene autoleucel for relapsed or refractory ...
2022年3月7日 · On February 28, 2022, the Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory...
CARVYKTI® (ciltacabtagene autoleucel) Receives …
2024年3月15日 · CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma...
CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease ...
2023年6月5日 · CARVYKTI ® is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient's own T-cells with a transgene encoding chimeric antigen receptor (CAR)...
J&J : Canada Approves CARVYKTI For Relapsed Or Refractory …
1 天前 · The authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI reduced the risk of disease progression or death by 74 per cent compared to ...